Please find below the March issue of EIPG's monthly newsletter.
this issue you will find an article originated from
valuable contribution of
and Thomas Lion
Impact of the emergence of precisions medicines in clinical trials
The development of precisions medicines requires to rethink the design of
clinical studies in order to capture specificities of this class of medicines.
Many are the points to be considered, from the use of companion diagnostics to
the choice to run solid or liquid biopsies and the optimisation of phase-I
studies in order to identify early signs of toxicity. Belgium is among the
leading European countries for number of clinical trials. The emergence of new,
innovative types of therapies, i.e. advanced therapies (ATMPs) such as CAR-T or
immuno-oncology products, asks for an updating of the traditional way to plan,
design and run clinical trials.
the monthly update from EIPG
, our members are asked to provide their comments
on EMA guidelines
on purity of water, development of topical products and
environmental risk assessment. You will also find a
report from the Supply
Working Group of the European Medicines Shortages Research Network
report on the
General Assembly of UPIP-VAPI. Finally, EPSA's
: a platform, which connects students (mentees) with
professionals (mentors), enable their collaboration in a structured way and
provide tools to follow up on achievements and gained knowledge.